Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | FASN | P49327 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4870615 | 0.88 | GAA (0.36) | — | |
| SCHEMBL4872963 | 0.86 | SYK (0.37) | KMT2AMEN1MAPTHPGD | |
| SCHEMBL4868006 | 0.83 | ALDH1A1 (0.39) | KDM4EKMT2AALDH1A1MEN1HPGD | |
| SCHEMBL4870360 | 0.83 | POLB (0.34) | KDM4EKMT2AEPHX2POLBFASN | |
| SCHEMBL4870364 | 0.83 | POLB (0.34) | KDM4EKMT2AEPHX2POLBFASN | |
| SCHEMBL4867298 | 0.81 | KDM4E (0.34) | KDM4EKMT2AEPHX2MAPTPOLB | |
| SCHEMBL4866372 | 0.81 | POLB (0.35) | KDM4EKMT2AALDH1A1EPHX2POLB | |
| SCHEMBL4866379 | 0.81 | POLB (0.35) | KDM4EKMT2AALDH1A1EPHX2POLB | |
| SCHEMBL4868134 | 0.80 | — | — | |
| SCHEMBL4867094 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7332485-B2 | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORP (US) | 2008-02-19 | — | — | US | disclosed |
| US-20060160802-A1 | Peptide deformylase inhibitors | GLAXO GROUP LIMITED | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160802-A1 | Peptide deformylase inhibitors | PDF, PEPD, DPEP1 | KDM4E 2591/4885KMT2A 3860/4885ALDH1A1 4302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.